PIA
JNCE

Piedmont Investment Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Piedmont Investment Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-274
Closed -$2K – 2501
2018
Q2 		$2K Buy
+274
New +$3.95K ﹤0.01% 2670

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Piedmont Investment Advisors's JNCE Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2018, closing a stake of 274 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in JNCE in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 274 Jounce Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $2K in Q2 2018.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.